(Reuters) – Biogen Inc’s experimental Alzheimer’s disease drug was found effective enough in a large trial to support approval, a U.S. Food and Drug Administration panel said on Wednesday, boosting the chances of a swift approval of the drug.
As a next step to a regulatory approval, the drug will be reviewed by FDA’s independent experts in a meeting on Friday that will make recommendations to the agency.
U.S. Food and Drug Administration’s independent experts will consider the remarks in a meeting on Friday, before making their recommendations to the agency.
A final decision on the drug, jointly developed with Japan’s Eisai Co Ltd, is due by March 2021.
(Reporting by Manas Mishra and Manojna Maddipatla in Bengaluru; Editing by Shinjini Ganguli)
